To receive CME credit for this program:
- Read the CME information and mark the checkbox confirming you have read the disclosures to download the PDF file below
- Review the article and illustration
- Login or register at the CME post test website (http://www.bucmetest.com)
- Locate the course code I.ANG11CRTHY and take the test
Jointly sponsored by Boston University School of Medicine and the Angiogenesis Foundation
ACCREDITATION STATEMENT
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Sponsorship of Boston University School of Medicine and the Angiogenesis Foundation. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Boston University School of Medicine designates this Internet activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Credit will be awarded provided this activity is used and completed according to instructions and a score of 70% or better is achieved. A certificate of credit will be issued to those who successfully complete the examination.
RELEASE AND EXPIRATION
Date of original release: January 30, 2011
Date of expiration: January 29, 2012
Estimated Time To Complete: 1.5 Hours
CME Course Code: I.ANG11CRTHY
TARGET AUDIENCE
Practicing oncologists in the U.S., researchers and medical students
HEALTHCARE GAP
Antiangiogenic therapy represents a relatively new approach to colorectal and thyroid cancer management. There is a critical need to educate physicians about the scientific and clinical rationale for pharmacological angiogenesis inhibition; cellular pathways and mechanisms involved in tumor angiogenesis; integration of antiangiogenic agents into traditional cancer therapy protocols; efficacy and safety data from completed or ongoing clinical trials; and information about novel imaging techniques and biomarkers for assessing response to targeted therapies and selecting patients for treatment. Although many sources of cancer information are available to oncologists, the Targeting Tumor Angiogenesis CME series provides a comprehensive overview on antiangiogenic cancer treatments, supported by unique graphical representation of concepts of cell signaling pathways and therapeutic targets. Leading oncology experts on antiangiogenic therapies provide a clinical perspective to the topics covered.
PROGRAM LEARNING OBJECTIVES
At the conclusion of this educational activity, clinicians will be able to:
- Describe the clinical rationale for targeting tumor angiogenesis in cancer treatment.
- Identify the molecular targets of both biologic and small molecule agents and how disruption of these targets inhibits cancer growth and spread.
- Discuss recent clinical efficacy data from clinical studies of antiangiogenic agents for the treatment of metastatic colorectal cancer and metastatic thyroid cancer.
- Describe common side effects from antiangiogenic therapies for cancer and how they can be managed.
METHOD OF PARTICIPATION
There are no fees for participating in and receiving credit for this online educational activity. The participant should, in order, read the objectives and faculty disclosures, review the educational content, answer the multiple-choice post-test and complete the evaluation. This program is available in PDF format accessible from the Angiogenesis Foundation's website (http://www.angio.org) in the CME section. A print version is also available; for more information contact outreach@angio.org. After reviewing the material, CME credits are available through the Boston University School of Medicine's website (http://www.bucmetest.com) by selecting the name of the program (registration required). Course code: I.ANG11CRTHY.
ACKNOWLEDGEMENT OF SUPPORT
This activity is supported by educational grants from AstraZeneca and Bayer/Onyx.
COURSE FACULTY
Jeffrey A. Meyerhardt, M.D., M.P.H.
Assistant Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Steven I. Sherman, M.D.
Chair and Naguib Samaan Distinguished Professor in Endocrinology
Medical Director, Endocrine Multidisciplinary Center
University of Texas MD Anderson Cancer Center, Houston
DISCLOSURE
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Jeffrey Meyerhardt, M.D., M.P.H., Dana-Farber Cancer Institute
Faculty
Dr. Meyerhardt has nothing to disclosure with regard to commercial interests.
Steven I. Sherman, M.D., University of Texas MD Anderson Cancer Center,
Faculty
Dr. Sherman receives grant/research support from Amgen, AstraZeneca, and Genzyme, and is a consultant for AstraZeneca, Bayer, Eisai, Exelixis, Novo Nordisk, Pfizer, and Veracyte.
William W. Li, M.D.,
President, the Angiogenesis Foundation, Editor-in-Chief
Dr. Li has nothing to disclose with regard to commercial interests.
Vickie R. Driver, DPM, M.S., FACFAS, Associate Professor of Surgery, Boston University School of Medicine
Course Director
Dr. Driver receives grant/research support from KCI, sanofi-aventis, 3M, and Baxter. She serves on the Scientific Steering Committee for sanofi-aventis.
Jody Walker, M.S.
BUSM CME Program Manager
BUSM CME Program Manager has nothing to disclose with regard to commercial interests.
Roderick A. Smith, M.S.
Medical Writer, Program Manager, the Angiogenesis Foundation
Medical Writer, Program Manager has nothing to disclose with regard to commercial interests.
DISCUSSION OF UNLABELLED USE
This CME activity contains discussion of published and/or investigational use of: axitinib (AG-013736), bevacizumab (Avastin®), Cediranib (Recentin®), cetuximab (Erbitux®), motesanib (AMG 706), panitumumab (Vectibix®), pazopanib (Votrien®), sorafenib (Nexavar®), sunitinib (Sutent®), vandetanib, VEGF Trap (Aflibercept), and XL184.
PRIVACY POLICY
The Office of Continuing Medical Education adheres to Boston University’s Conditions of Use and Policy on Computing Ethics. <http://www.bu.edu/cme/policies/privacy_policy.html>
Data gathered from participants who participate in Boston University School of Medicine’s (BUSM) Continuing Medical Education Internet-Based CME program is confidential.
Individual identifiable information is not shared with outside parties. Cumulative data may be analyzed by CME personnel, and, upon occasion, by individuals external to BUSM CME in order to determine trends.
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLEY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKE NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
TOPICS AND EDUCATIONAL CONTENT
Antiangiogenic therapy for metastatic colorectal cancer
- Bevacizumab
- Novel therapies and combinations
- Side effects of antiangiogenic therapy
- Conclusions and future directions
Antiangiogenic therapy for metastatic thyroid cancer
- Anti-VEGFR tyrosine kinase inhibitors
- Safety
- Conclusions and future directions
SYSTEM REQUIREMENTS
This educational program is available in PDF format. To view and print PDF files, you must have Adobe Reader installed on your computer. Most computers already have this software installed. If yours does not, you can download Adobe Reader free from the Adobe Web site: http://www.adobe.com.
If you have questions regarding certificates, please contact BUSM CME by email at cme@bu.edu or visit http://www.bu.edu/cme
For questions about this program, please contact the Angiogenesis Foundation at 617-401-2779 or outreach@angio.org.
Copyright 2011 by the Angiogenesis Foundation. All rights reserved.
|
